biopharmaceuticals

Lars began by emphasizing the urgency of advancing biotechnology safely. I reassured him that this is possible, highlighting two key factors: aggressive private sector investment, federally funded basic research, and science-based regulation.

Recently the U.S. Food and Drug Administration granted accelerated approval to aducanumab (Aduhelm), the first Alzheimer’s Disease treatment since 2003.